News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Study Status:

Open for enrollment

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To evaluate the safety and tolerability of once-daily, oral administration of resmetirom for 52 weeks.

Information: 

Principal Investigator
Fernando Membreno, MD
Co-PI
John Rodriguez
Sponsor
Madrigal Pharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram